Literature DB >> 21372217

Direct effects of type I interferons on cells of the immune system.

Sandra Hervas-Stubbs1, Jose Luis Perez-Gracia, Ana Rouzaut, Miguel F Sanmamed, Agnes Le Bon, Ignacio Melero.   

Abstract

Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and antiangiogenesis via signaling through a common receptor interferon alpha receptor (IFNAR). IFNAR induces the Janus activated kinase-signal transducer and activation of transcription (JAK-STAT) pathway in most cells, along with other biochemical pathways that may differentially operate, depending on the responding cell subset, and jointly control a large collection of genes. IFNs-I were found to systemically activate natural killer (NK) cell activity. Recently, mouse experiments have shown that IFNs-I directly activate other cells of the immune system, such as antigen-presenting dendritic cells (DC) and CD4 and CD8 T cells. Signaling through the IFNAR in T cells is critical for the acquisition of effector functions. Cross-talk between IFNAR and the pathways turned on by other surface lymphocyte receptors has been described. Importantly, IFNs-I also increase antigen presentation of the tumor cells to be recognized by T lymphocytes. These IFN-driven immunostimulatory pathways offer opportunities to devise combinatorial immunotherapy strategies. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372217     DOI: 10.1158/1078-0432.CCR-10-1114

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  199 in total

1.  Control of type I interferon-induced cell death by Orai1-mediated calcium entry in T cells.

Authors:  Chanyu Yue; Jonathan Soboloff; Ana M Gamero
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

2.  Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.

Authors:  Bin Du; David J Waxman
Journal:  Cancer Lett       Date:  2019-11-22       Impact factor: 8.679

3.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 4.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 5.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 6.  Decoding the complexity of type I interferon to treat persistent viral infections.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Trends Microbiol       Date:  2013-11-08       Impact factor: 17.079

7.  Human disease modeling reveals integrated transcriptional and epigenetic mechanisms of NOTCH1 haploinsufficiency.

Authors:  Christina V Theodoris; Molong Li; Mark P White; Lei Liu; Daniel He; Katherine S Pollard; Benoit G Bruneau; Deepak Srivastava
Journal:  Cell       Date:  2015-03-12       Impact factor: 41.582

8.  Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses.

Authors:  Ewa M Kosciuczuk; Swarna Mehrotra; Diana Saleiro; Barbara Kroczynska; Beata Majchrzak-Kita; Pawel Lisowski; Caroline Driehaus; Anna Rogalska; Acara Turner; Thomas Lienhoop; David Gius; Eleanor N Fish; Athanassios Vassilopoulos; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2018-11-28       Impact factor: 5.157

Review 9.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 10.  Melanoma immunotherapy.

Authors:  Martina Sanlorenzo; Igor Vujic; Christian Posch; Akshay Dajee; Adam Yen; Sarasa Kim; Michelle Ashworth; Michael D Rosenblum; Alain Algazi; Simona Osella-Abate; Pietro Quaglino; Adil Daud; Susanna Ortiz-Urda
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.